Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, today announced that the first patient has been dosed in the phase 1 clinical programme of CT7001 Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-its-oral-cdk7-inhibitor-ct7001-5517